Wernicke encephalopathy is a medical emergency where a severe lack of vitamin B1 damages the brain, often in people with alcohol use disorder. If not treated quickly and properly, it can lead to lasting disability or death. A new look at hospital records in Japan reveals a major shift in how doctors are trying to fight it: the use of high-dose thiamine injections at the start of treatment jumped from about 5% of patients to nearly half over a 13-year period. The study followed over 7,800 patients hospitalized with the condition. Treatment started quickly, typically on the first day. Yet, the findings are sobering. More than half of the patients—56%—were discharged with impaired abilities to care for themselves, like bathing or walking. The in-hospital death rate was 3.8%. It’s important to understand what this data can and cannot tell us. This was an observational study, meaning it described what happened in real-world practice. It did not compare different doses to see which one worked better or was safer. So, while it shows a clear trend toward using more thiamine, we don’t yet know if that higher dose is the right answer for improving a patient’s long-term function. The high rate of disability at discharge highlights how devastating this condition remains and signals a critical need for more research into the best treatment and prevention strategies.
High-dose thiamine use increased for Wernicke encephalopathy in Japan; functional impairment common at dischargeDid more high-dose vitamin B1 help patients with alcohol-related brain damage?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This observational study analyzed a nationwide inpatient database in Japan from 2010 to 2024, including 7,856 patients hospitalized with Wernicke encephalopathy. It described trends in initial intravenous thiamine dosing, categorized as low (≤300 mg/day), medium (301-900 mg/day), or high (>900 mg/day). The proportion of patients receiving high-dose thiamine increased from 5.4% to 49.0% over the 13-year period, while low-dose use decreased from 83.0% to 37.9%. The median time to initial thiamine administration was 0 days (interquartile range, 0 to 0 days).
Regarding outcomes, 56.1% of patients were discharged with impaired activities of daily living, defined as a Barthel Index score below 90. The in-hospital mortality rate was 3.8%. The study did not report comparative effectiveness analyses between dose groups for these outcomes. Safety and tolerability data for the thiamine doses were not reported.
Key limitations include the study's observational and descriptive nature, which reports associations rather than establishing causation. The authors note limited clinical evidence on contemporary management and functional outcomes for this condition. The high prevalence of functional impairment at discharge indicates a substantial disease burden despite early treatment initiation.
For practice, this study documents a clear trend toward higher initial thiamine dosing in Japanese hospitals. However, the optimal thiamine dose and the effectiveness of prevention strategies for Wernicke encephalopathy remain areas requiring further research, as this analysis cannot determine which dosing strategy leads to better patient outcomes.
View Original Abstract ↓
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
From Other Specialties
